{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-040288","form_type":"8-K","ticker":"ELTP","cik":"0001053369","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2024-10-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.510511+00:00","generated_at":"2026-05-30T18:57:14.881134+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Elite Pharmaceuticals launches generic Tylenol with Codeine tablets across three strengths","bullets":["Launched generic acetaminophen/codeine phosphate tablets in 300mg/15mg, 300mg/30mg, 300mg/60mg.","Product marketed under Elite Laboratories label for mild to moderate pain management.","US market for these tablets approximated $47M for 12 months ended May 2024 (IQVIA).","Launch expands Elite's niche generic portfolio; company operates cGMP/DEA facility in Northvale, NJ."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-040288","json":"https://secwatch.observer/filing/0001493152-24-040288.json","markdown":"https://secwatch.observer/filing/0001493152-24-040288.md","text":"https://secwatch.observer/filing/0001493152-24-040288.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315224040288/0001493152-24-040288-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315224040288/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T18:57:14.881134+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}